All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Article

Equipment and Processing Report

June 20, 2018

Equipment and Processing Report

Equipment and Processing Report-06-20-2018
Volume11
Issue 7

Trends in Primary Packaging Materials for Parenterals

Author(s):

Hallie Forcinio

Glass remains the most widely used primary packaging material for parenterals, but polymeric materials are an option.

Despite the proliferation of new drug delivery systems for parenteral products, glass vials remain the most widely used primary containers worldwide. This trend is expected to continue for several years, with global demand for glass vials projected to rise to $5.7 billion in 2024 (1). 

In fact, borosilicate glass has been the primary packaging choice for parenteral products since its development more than 100 years ago due to its excellent barrier properties, chemical resistance, regulatory acceptance, and broad range of applications served. 

But glass is not the only choice, especially for sensitive biotech products, and polymeric materials have captured market share in recent years. Polymeric materials offer light weight, shatter resistance, greater formability, tighter tolerances, strong barrier, and chemical compatibility. As a result, plastic packaging is gaining ground with global demand for plastic parenteral vials forecast to grow 7.7% per year to more than $1.6 billion (13.1 billion units) in 2021 (2). 

One popular polymeric option, cyclic olefin copolymer (COC), combines formability, break resistance, and light weight with a glass-like transparency. Other polymers such as cyclo-olefin polymer (COP) and polyethylene naphthalate (PEN) offer similar attributes. 

“The physical stability as well as the diverse design options make COC an attractive alternative for some drugs,” explains Tom Van Ginneken, global product manager SCHOTT TopPac at SCHOTT Pharmaceutical Systems, a supplier of glass and plastic packaging for parenteral products. Anna Malori, business development manager at Bormioli Pharma, a producer of pharmaceutical primary packaging both in glass and plastic, agrees and predicts, “Some fields of application for COC will be highly sensitive drugs, biotech drugs and vaccines, and high-value drugs such as oncology treatments.” 

Glass or plastic?

With glass and polymers offering advantages and limitations in different scenarios, many factors must be considered to determine the better choice. Commercializing new primary packaging for parenteral products tends to be time-consuming due to the complex regulatory approval procedures that must be followed to adopt a new packaging material. “The regulatory approval process can take years, and that is why each single change in the glass vial configuration may be seen as an obstacle toward the final drug product approval,” explains Malori. 

As a result, many producers of glass packaging for parenteral products are leaving glass chemistry unchanged, but they are fine-tuning processes and quality control practices and increasing inspection capabilities to ensure shipment of flawless finished containers.  

Malori says: “Each packaging choice should be strictly related to the specific needs and characteristics of the formulation that will be contained inside.” Working in close collaboration, the packaging supplier and drug maker identify the best packaging material and container-closure system for the formulation. Once that decision is finalized, suppliers provide support during the validation process. 

Ginneken details the holistic approach: “We consider what we call the three Ps-product, process, and patient. For example, we examine specific requirements for the drug. Does it need a particularly inert packaging? We also look at the process requirements to consider how the product will be integrated into existing manufacturing lines or how to create a low-waste filling process, among others. Lastly, we focus on the patient as we aim to continuously meet the patient’s comfort and needs. Therefore, we study if drug delivery in a home setting is required. If so, the primary packaging must be easy to handle for the patient and work with self-administration devices.”

References

1. Freedonia, “World Pharmaceutical Packaging Industry Study #3269,” July 2015, p. 73-75. 

2. Freedonia, “World Pharmaceutical Packaging Industry Study #3591,” January 2018, p. 66-67.

About the author

Hallie Forcinio is Pharmaceutical Technology's packaging editor.

Articles in this issue

Trends in Primary Packaging Materials for Parenterals
Robotics Solve Aseptic Filling Challenges

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Advertisement
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
July 25th 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Oil painting of maze with figure finding way through. Perseverance, problem-solving. Birds fly above labyrinth at sunset. Concept of challenges, resilience, journey, overcoming obstacles in business | Image Credit © Vadym - stock.adobe.com
July 25th 2025

CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success

Christopher Cole
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and analytical issues despite early regulatory guidance. Review key risk points in analytical and tech transfer to better ensure commercial readiness.
Site Logo
March 28th 2025

Transformations in Drug Development for Cell and Gene Therapies

PPD Thermo Fisher Scientific
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Sand running through the bulbs of an hourglass | Image Credit: © BillionPhotos.com - stock.adobe.com
July 24th 2025

Customizable Relationships Enhance Speed to Market

Patrick Lavery
While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
Related Content
Advertisement
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
July 25th 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Oil painting of maze with figure finding way through. Perseverance, problem-solving. Birds fly above labyrinth at sunset. Concept of challenges, resilience, journey, overcoming obstacles in business | Image Credit © Vadym - stock.adobe.com
July 25th 2025

CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success

Christopher Cole
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and analytical issues despite early regulatory guidance. Review key risk points in analytical and tech transfer to better ensure commercial readiness.
Site Logo
March 28th 2025

Transformations in Drug Development for Cell and Gene Therapies

PPD Thermo Fisher Scientific
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Sand running through the bulbs of an hourglass | Image Credit: © BillionPhotos.com - stock.adobe.com
July 24th 2025

Customizable Relationships Enhance Speed to Market

Patrick Lavery
While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.